Abivax S.A.
ABVX.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €0 | €0 | €0 | €0 |
| % Growth | 133.5% | 0.8% | 12,286.5% | – |
| Cost of Goods Sold | €0 | €0 | €0 | €0 |
| Gross Profit | €0 | €0 | €0 | -€0 |
| % Margin | 100% | 97.2% | 98.5% | -321.6% |
| R&D Expenses | €0 | €0 | €0 | €0 |
| G&A Expenses | €0 | €0 | €0 | €0 |
| SG&A Expenses | €0 | €0 | €0 | €0 |
| Sales & Mktg Exp. | €0 | €0 | €0 | €0 |
| Other Operating Expenses | -€0 | -€0 | €0 | -€0 |
| Operating Expenses | €0 | €0 | €0 | €0 |
| Operating Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | -1,718.2% | -2,756.5% | -1,414.7% | -141,045.9% |
| Other Income/Exp. Net | €0 | -€0 | -€0 | €0 |
| Pre-Tax Income | -€0 | -€0 | -€0 | -€0 |
| Tax Expense | -€0 | -€0 | -€0 | -€0 |
| Net Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | -1,633.1% | -3,197.1% | -1,325.3% | -114,735.1% |
| EPS | -2.8 | -3.43 | -3.18 | -2.75 |
| % Growth | 18.4% | -7.9% | -15.6% | – |
| EPS Diluted | -2.8 | -3.43 | -3.18 | -2.75 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | €0 | €0 | €0 |
| Interest Expense | €0 | €0 | €0 | €0 |
| Depreciation & Amortization | €0 | €0 | €0 | €0 |
| EBITDA | -€0 | -€0 | -€0 | -€0 |
| % Margin | -1,553.8% | -2,882.6% | -1,163.3% | -114,040.5% |